RBC Capital analyst Frank Morgan raised his price target on Ensign Group to $27 and kept his Outperform rating despite the "turmoil" in the skilled nursing industry. Morgan says the time he has spent with the company's non-deal roadshow suggest that its operations should steadily improve and the drag of rising insurance costs can be mitigated next year. The analyst adds that the management continues to explore the value-creating opportunities within its enterprise, including its owned real estate portfolio, while the company is also likely to do some smaller acquisitions into early 2018.